Recent guidelines recommend that patients who failed DAAs treatment with nonstructural protein 5A inhibitors (NS5A) should be retreated 24 weeks with Sofosbuvir (SOF) combined with either a protease inhibitor for… Click to show full abstract
Recent guidelines recommend that patients who failed DAAs treatment with nonstructural protein 5A inhibitors (NS5A) should be retreated 24 weeks with Sofosbuvir (SOF) combined with either a protease inhibitor for those with NS5A RAVs, or with a NS5A inhibitor for those without NS5A RAVs (1, 6, 7). Little is known on real life retreatment of patients who had failed to achieve sustained virological response (SVR) on previous NS5A-based therapy (1).
Keywords:
active antivirals;
antivirals genotype;
genotype chronic;
retreatment;
direct active;
retreatment direct
Journal Title: Journal of Hepatology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Hepatology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!